Introduction {#s1}
============

The [Reproducibility Project: Cancer Biology](https://osf.io/e81xl/wiki/home/) (RP:CB) is a collaboration between the [Center for Open Science](https://centerforopenscience.org/) and [Science Exchange](https://www.scienceexchange.com/) that seeks to address concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology ([@bib3]). For each of these papers a Registered Report detailing the proposed experimental designs and protocols for the replications was peer reviewed and published prior to data collection. The present paper is a Replication Study that reports the results of the replication experiments detailed in the Registered Report ([@bib8]) for a paper by Sirota et al., and uses a number of approaches to compare the outcomes of the original experiments and the replications.

In 2011, Sirota et al. presented a computational approach to identify drugs that could be repurposed for alternative diseases. Cimetidine, an H2 receptor blocker used to treat gastric ulcers ([@bib11]), was predicted to be a therapeutic approach for lung adenocarcinoma. Using a xenograft model with the A549 lung adenocarcinoma cell line, cimetidine resulted in a statistically significant decrease in tumor volume on the last day of the experiment compared to vehicle control ([@bib15]). A decrease in tumor volume was also observed with the chemotherapeutic agent doxorubicin, a positive control therapy. Cimetidine treatment was also tested in mice implanted with the ACHN renal cell carcinoma cell line, which did not change tumor volume compared to vehicle control. This was in agreement with the prediction and demonstrated specificity of the approach by Sirota and colleagues ([@bib15]).

The Registered Report for the paper by Sirota et al. described the experiments to be replicated (Figure 4C--D and Supplemental Figure 1), and summarized the current evidence for these findings ([@bib8]). The outcome measures reported in this Replication Study will be aggregated with those from the other Replication Studies to create a dataset that will be examined to provide evidence about reproducibility of cancer biology research, and to identify factors that influence reproducibility more generally.10.7554/eLife.17044.002Figure 1.Tumor xenograft experiment testing efficacy of cimetidine in inhibiting the growth of tumors in SCID mice.Female SCID mice bearing subcutaneous A549 human lung adenocarcinomas (**A**) or ACHN renal cell carcinomas (**B**) were randomized into three treatment groups once tumors reached a calculated volume of 100 mm^3^. Mice were intraperitoneally injected with 100 mg/kg cimetidine, vehicle (PBS), or 2 mg/kg doxorubicin. Tumor volumes were measured by caliper for the duration of the study. For each condition tumor volume was normalized relative to the average Day 1 values. Means reported and error bars represent s.e.m. Number of mice: (**A**) A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin) (**B**) ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Two-tailed Welch's *t*-test on Day 11 relative volumes between vehicle or doxorubicin treated A549 tumors; *t*(6.73) = 2.68, uncorrected *p*=0.0325 with *a priori* alpha level = 0.0167; (Bonferroni corrected *p*=0.0976). Two-way ANOVA interaction between cell line (A549 or ACHN) and treatment (vehicle or cimetidine) on natural log transformed Day 11 relative volumes; *F*(1,53) = 3.88, *p*=0.054. Pairwise contrast between A549 tumors treated with vehicle or cimetidine; *t*(53) = 2.16, uncorrected *p*=0.035 with *a priori* alpha level = 0.0167; (Bonferroni corrected *p*=0.105). Pairwise contrast between ACHN tumors treated with vehicle or cimetidine; *t*(53) = 0.58, uncorrected *p*=0.562 with *a priori* alpha level = 0.0167; (Bonferroni corrected p\>0.99). Additional details for this experiment can be found at <https://osf.io/fh6gn/>.**DOI:** [http://dx.doi.org/10.7554/eLife.17044.002](10.7554/eLife.17044.002)10.7554/eLife.17044.003Figure 1---figure supplement 1.Individual tumor xenografts.This is the same experiment as in [Figure 1](#fig1){ref-type="fig"}, but with the data plotted for each animal rather than averages. Female SCID mice bearing subcutaneous A549 human lung adenocarcinomas (**A**) or ACHN renal cell carcinomas (**B**) were intraperitoneally injected with 100 mg/kg cimetidine, vehicle (PBS), or 2 mg/kg doxorubicin. For each condition tumor volume was normalized relative to the average Day 1 values. Number of mice: (**A**) A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin) (**B**) ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Additional details for this experiment can be found at <https://osf.io/fh6gn/>.**DOI:** [http://dx.doi.org/10.7554/eLife.17044.003](10.7554/eLife.17044.003)

Results and discussion {#s2}
======================

Assessing the effect of cimetidine treatment on tumor growth in a xenograft model of lung carcinoma and a xenograft model of renal carcinoma {#s2-1}
--------------------------------------------------------------------------------------------------------------------------------------------

We sought to independently replicate the effectiveness of cimetidine treatment as a possible therapeutic agent for lung adenocarcinoma, but not renal cell carcinoma, by performing an experiment in mice implanted with the A549 or ACHN cell lines, respectively. This experiment is similar to what was reported in Figure 4C--D and Supplemental Figure 1 of [@bib15]. Tumor volume was determined by caliper daily for the duration of the study ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). While the original study included three doses of cimetidine in the experimental design, this replication attempt was restricted to only the highest dose (100 mg/kg). Tumors from A549 cells treated with cimetidine grew to an average of 2.37 times their original volume by day 11 \[n=13, *SD*=0.723\], similar to the \~2.3 times reported in the original study. This is in comparison to tumors from A549 cells treated with vehicle, which grew to an average of 3.29 times their original volume by day 11 \[n=14, *SD*=1.17\], similar to the \~3.3 times reported in the original study. Tumors from ACHN cells treated with vehicle or cimetidine grew to an average of 2.96 \[n=15, *SD*=0.952\] or 3.37 \[n=15, *SD*=1.50\] times their original volume by day 11, respectively. ACHN derived tumors were similar in volume compared to tumors from A549 cells treated with vehicle in this study. This differed from the tumor volumes reported in [@bib15], which were \~2.1 and \~2.0 times the original volume in tumors from ACHN cells treated with vehicle or cimetidine, respectively, compared to \~3.3 times the original volume in tumors from A549 cells treated with vehicle. Additionally, the relative standard deviation (RSD) associated with this replication attempt (A549 -- vehicle treated = 35.6%; A549 -- cimetidine treated = 30.5%; ACHN -- vehicle treated = 32.1%; ACHN -- cimetidine treated = 44.5%) was generally larger than the RSD observed in the original study (A549 -- vehicle treated = 17.0%; A549 -- cimetidine treated = 35.5%; ACHN -- vehicle treated = 10.3%; ACHN -- cimetidine treated = 12.0%), however, the range of RSD among the conditions was more consistent in this replication attempt compared to the original study.

There are multiple approaches that could be taken to explore these data (e.g. MANOVA, regression with RE/AR errors, area under the curve), however to provide a direct comparison to the original analysis, which used volume measurements at day 11, and the available original data, we are reporting the analysis specified *a priori* in the Registered Report ([@bib8]). To test if cimetidine is effective in the A549 derived xenograft model, but not in the ACHN derived xenograft model, we performed an analysis of variance (ANOVA) having two levels of tumors (A549 derived or ACHN derived) and two levels of drug treatment (vehicle or cimetidine). The ANOVA result on tumor volumes at day 11 (natural log-transformed) was not statistically significant for all effects at the 0.05 significance level. The interaction effect, with a sample size powered *a priori* to detect the effect based on the originally reported data, was not statistically significant, *F*(1,53) = 3.88, *p*=0.054. Thus, the null hypothesis that the effect of the drug treatment (difference between vehicle and cimetidine) on inhibiting tumor volume growth is similar for A549 and ACHN derived tumors can not be rejected. The main effect for cell line, *F*(1,53) = 1.21, *p*=0.277, and drug treatment *F*(1,53) = 1.13, *p*=0.292 were also not statistically significant.

As outlined in the Registered Report ([@bib8]), we planned to conduct three comparisons using the Bonferroni correction to adjust for multiple comparisons. Although the Bonferroni method is conservative, it was accounted for in the power calculations to ensure sample size was sufficient. The planned pairwise comparison of the tumor volumes from A549 derived tumors treated with vehicle compared to cimetidine was not statistically significant (*t*(53) = 2.16, uncorrected *p*=0.035, *a priori* Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*=0.105)). Additionally, the planned pairwise comparison of ACHN derived tumors treated with vehicle compared to cimetidine was not statistically significant (*t*(53) = −0.58, uncorrected *p*=0.562, a prior Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*\>0.99)). While not statistically significant, the treatment of A549 derived tumors with cimetidine resulted in decreased tumor volume compared to vehicle control at day 11, which is in the same direction as the original study. The treatment of ACHN derived tumors with cimetidine did not result in an observational difference in tumor volume after treatment when compared to vehicle control treated tumors, similar to the original study.

As an additional control for tumor growth inhibition, tumors from A549 cells were treated with 2 mg/kg doxorubicin, similar to the original experimental design ([Figure 1A](#fig1){ref-type="fig"}). While tumors from A549 cells treated with vehicle grew to an average of 3.29 times their original volume by day 11, tumors in mice treated with doxorubicin grew to an average of 1.87 times the original volume by day 11 \[n=4, *SD*=0.845\], similar to the \~2.0 times, reported in [@bib15] in the doxorubicin condition. Analysis of vehicle treated compared to doxorubicin treated tumor volumes at day 11, which was planned *a priori*, was not statistically significant (Welch's *t*-test; *t*(6.73) = 2.68, uncorrected *p*=0.0325, *a priori* Bonferroni adjusted significance threshold = 0.0167; (Bonferroni corrected *p*=0.0976)). While not statistically significant, the treatment of tumors from A549 cells with doxorubicin resulted in a smaller volume when compared to vehicle control at day 11, which is in the same direction as the original study. Additionally, mice treated with doxorubicin started to lose weight and had a rough coat starting on approximately day 7 of the treatment schedule. A small reduction in tumor volume compared to vehicle control has also been reported in other studies that utilized low dose doxorubicin experimental designs ([@bib5]; [@bib12]; [@bib17], [@bib18]).

At the completion of the treatment schedule, tumors were excised and imaged (available at <https://osf.io/xcuh6/>), similar to the representative A549 derived tumors treated with vehicle or 100 mg/kg cimetidine shown in Figure 4D of the original study ([@bib15]). The excised tumors were also weighed ([Figure 2](#fig2){ref-type="fig"}), as described in the Registered Report ([@bib8]). This was an additional measured parameter not included in the original study. The tumor weights were subjected to a two-way ANOVA having two levels of cell lines (A549 derived or ACHN derived), two levels of treatment (vehicle or cimetidine), and their interaction. The main effect of cell lines yielded an *F* ratio of *F*(1,53) = 7.560, *p*=0.00814, indicating that the mean tumor weight was significantly larger for A549 derived tumors \[n=27, *M*=0.138, *SD*=0.0423\] than for ACHN derived tumors \[n=30, *M*=0.108, *SD*=0.0402\]. The main effect of treatment was not significant (*F*(1,53) = 0.586, *p*=0.447) nor was the interaction effect (*F*(1,53) = 0.00005, *p*=0.994). Exploratory analysis of vehicle treated \[n=14, *M*=0.134, *SD*=0.0444\] compared to doxorubicin treated \[n=4, *M*=0.110, *SD*=0.0576\] A549 derived tumor weights was not statistically significant (Welch's *t*-test; *t*(4.078) = 0.771, *p*=0.483). While not statistically significant, the treatment of tumors derived from A549 cells with doxorubicin resulted in a small effect (Cohen's *d* = 0.51 \[−0.62, 1.63\]), which is in the expected direction. A small reduction in tumor weight compared to vehicle control has also been reported in other studies that utilized a similar low dose doxorubicin experimental design ([@bib1]; [@bib5]; [@bib12]; [@bib18]).10.7554/eLife.17044.004Figure 2.Final tumor weights from xenograft experiment testing efficacy of cimetidine in inhibiting the growth of tumors in SCID mice.At the end of the predefined study period (Day 12), tumors from the xenograft experiment reported in [Figure 1](#fig1){ref-type="fig"} were excised and weighed. Box and whisker plot with median represented as the line through the box, means represented as the solid red circle, and whiskers representing values within 1.5 IQR of the first and third quartile. Number of mice: A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin). ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Two-tailed Welch's *t*-test between vehicle or doxorubicin treated A549 tumors; *t*(4.078) = 0.771, *p*=0.483. Two-way ANOVA interaction between cell line (A549 or ACHN) and treatment (vehicle or cimetidine); *F*(1,53) = 0.00005, *p*=0.994. Two-way ANOVA main effect of cell line (A549 or ACHN); *F*(1,53) = 7.56, *p*=0.00814. Additional details for this experiment can be found at <https://osf.io/fh6gn/>.**DOI:** [http://dx.doi.org/10.7554/eLife.17044.004](10.7554/eLife.17044.004)

Meta-analyses of original and replicated effects {#s2-2}
------------------------------------------------

We performed a meta-analysis using a random-effects model to combine each of the effects described above on day 11 tumor volume comparisons as pre-specified in the confirmatory analysis plan ([@bib8]). To provide a standardized measure of the effect Cohen's *d* was calculated for the original and replication studies. Cohen's *d* is the standardized difference between two means using the pooled sample standard deviation.

The comparison of A549 derived tumor volumes treated with vehicle compared to cimetidine resulted in *d* = 1.36, 95% CI \[0.06, 2.60\] for the data estimated *a priori* from Figure 4C of the original study ([@bib15]). This compares to *d* = 0.93, 95% CI \[0.12, 1.72\] reported in this study. A meta-analysis ([Figure 3](#fig3){ref-type="fig"}) of these two effects resulted in *d* = 1.04, 95% CI \[0.33, 1.75\], *p*=0.0043. Both results are consistent when considering the direction of cimetidine's effect. The point estimate of the replication effect size was within the confidence interval of the original result and vice versa. Further, the random effects meta-analysis resulted in a statistically significant effect of cimetidine on inhibiting A549 derived tumors.10.7554/eLife.17044.005Figure 3.Meta-analyses of each effect.Effect size (Cohen's *d*) and 95% confidence interval are presented for [@bib15], this replication attempt (RP:CB), and a meta-analysis to combine the two effects of day 11 tumor volume comparisons. Sample sizes used in [@bib15] and this replication attempt are reported under the study name. Random effects meta-analysis of A549-derived tumors treated with vehicle (PBS) compared to 100 mg/kg cimetidine (meta-analysis *p*=0.0043), ACHN-derived tumors treated with vehicle (PBS) compared to 100 mg/kg cimetidine (meta-analysis *p*=0.917), and A549-derived tumors treated with vehicle (PBS) compared to 2 mg/kg doxorubicin (meta-analysis *p*=0.021). Additional details for these meta-analyses can be found at <https://osf.io/jcghv/>.**DOI:** [http://dx.doi.org/10.7554/eLife.17044.005](10.7554/eLife.17044.005)

The comparison of ACHN derived tumor volumes treated with vehicle compared to cimetidine resulted in *d* = 0.61, 95% CI \[−0.57, 1.76\] for the data estimated *a priori* from Supplemental Figure 1 of the original study ([@bib15]). This compares to *d* = −0.18, 95% CI \[−0.90, 0.54\] reported in this study. A meta-analysis ([Figure 3](#fig3){ref-type="fig"}) of these two effects resulted in *d* = 0.04, 95% CI \[−0.65, 0.73\], *p*=0.917. The original and replication results were both not statistically significant. While both studies were in opposite directions, the point estimate of the replication effect size was within the confidence interval of the original result, but the original effect size was not within the confidence interval of the replication. The random effects meta-analysis did not result in a statistically significant effect suggesting there is no evidence that cimetidine is effective on ACHN derived tumors.

The comparison of A549 derived tumors treated with vehicle compared to doxorubicin resulted in *d* = 3.00, 95% CI \[1.25, 4.70\] for the data estimated *a priori* from Figure 4C of the original study ([@bib15]). This compares to *d* = 1.26, 95% CI \[0.05, 2.44\] reported in this study. A meta-analysis ([Figure 3](#fig3){ref-type="fig"}) of these two effects resulted in *d* = 1.98, 95% CI \[0.30, 3.66\], *p*=0.021. Both results are consistent when considering the direction of doxorubicin's effect. The point estimate of the replication effect size was within the confidence interval of the original result, while the point estimate of the original effect size was not within the confidence interval of the replication result. Further, the random effects meta-analysis resulted in a statistically significant effect of doxorubicin on inhibiting A549 derived tumors.

This direct replication provides an opportunity to understand the present evidence of these effects. Any known differences, including reagents and protocol differences, were identified prior to conducting the experimental work and described in the Registered Report ([@bib8]). However, this is limited to what was obtainable from the original paper, which means there might be particular features of the original experimental protocol that could be critical, but unidentified. So while some aspects, such as site of injection, number of cells injected, strain of mice, and manufacturer of the drugs were maintained, others were unknown or not easily controlled for. These include variables such as circadian biological responses to therapy ([@bib4]), mouse sex and strain stocks ([@bib2]), the microbiome of recipient mice ([@bib13]), housing temperature in mouse facilities ([@bib10]), cell line drift ([@bib6]), and differing compound potency resulting from different stock solutions ([@bib9]). Whether these or other factors influence the outcomes of this study is open to hypothesizing and further investigation, which is facilitated by direct replications and transparent reporting.

Materials and methods {#s3}
=====================

As described in the Registered Report ([@bib8]), we attempted a replication of the experiments reported in Figures 4C--D and Supplemental Figure 1 of [@bib15]. A detailed description of all protocols can be found in the Registered Report ([@bib8]). Additional detailed experimental notes, data, and analysis are available on the Open Science Framework (OSF) (RRID: [SCR_003238](https://scicrunch.org/resolver/SCR_003238)) (<https://osf.io/hxrmm/>[; [@bib7]](https://osf.io/hxrmm/)).

Cell culture {#s3-1}
------------

A549 cells (ATCC, CCL-185) were maintained in F-12 Ham's medium supplemented with 10% Fetal Bovine Serum (FBS) (Sigma-Aldrich, cat \# F2442) and 2 mM sodium pyruvate. ACHN cells (ATCC, CRL-1611) were maintained in EMEM supplemented with 10% FBS, 2 mM glutamine, and 1 mM sodium pyruvate. All cells were grown at 37°C and at 5% CO~2~. Quality control data for the A549 and ACHN cell lines are available on the OSF (<https://osf.io/yt9fv/>). This includes results confirming the cell lines were free of mycoplasma contamination and common mouse pathogens. Additionally, STR DNA profiling of the cell lines was performed and all cells were confirmed to be the indicated cell lines when queried against STR profile databases.

Animals {#s3-2}
-------

All animal procedures were approved by the Northwestern University IACUC\# IS00000424 and were in accordance with the Northwestern University's policies on the care, welfare, and treatment of laboratory animals. No blinding occurred during the experiments.

Six-week old female SCID mice (Charles River, strain code 236) were inoculated subcutaneously (s.c.) with A549 or ACHN cells at a density of 5 × 10^6^ cells in 100 µl of Dulbecco's Phosphate Buffered Saline (DPBS) (Sigma-Aldrich, cat \# D8537) in the right upper flank. Tumor (caliper measurements) and body weight (scale: Scout Pro O'Haus, model \# SP202 (S/N: B443188875)) were measured three times a week before enrollment to reduce stress in the mice and were measured daily during the course of the experiment. Once the tumor reached 100 mm^3^, the mice were randomized into the treatment groups (vehicle (DPBS), 100 mg/kg cimetidine (dissolved in DPBS and pH adjusted and filtered through 0.22 µm syringe), or 2 mg/kg doxorubicin (dissolved in DPBS and filtered through 0.22 µm syringe)), taking into account the pre-specified group sizes. Two mice were not enrolled in the study due to unanticipated death and a small tumor size. Injections were administered via the intraperitoneal (IP) route using a 1 ml syringe (BD, cat \# Z192090) with 27 gauge needles (BD, cat \# 305109) as a repeat dose each day for cimetidine and twice a week for doxorubicin for 11 days with a dosing volume of 100 µl per 20 gram mouse. The volume of injection was calculated based on the total body weight obtained on the same day prior to injection. After repeat dosing for 11 days, all surviving animals were sacrificed 24 hr post last dose. Tumors were harvested and weighed (scale: Metler Toledo, Model \# XL300), with pictures of the tumors taken with a ruler for scale similar to the representative examples shown in Figure 4D of the original study (available at: <https://osf.io/xcuh6/>).

Each cage contained up to five mice and offered Certified Rodent Diet (Harlan Teklad, cat \# 7912) *ad libitum*. The animal room was set to maintain between 68--75°F, a relative humidity of 30--70%, a minimum of 15 room air changes per hour, and a 12 hr light/dark cycle, which was interrupted for study-related activities.

Statistical analysis {#s3-3}
--------------------

Statistical analysis was performed with R software (RRID: [SCR_001905](https://scicrunch.org/resolver/SCR_001905)), version 3.2.3 ([@bib14]). All data, csv files, and analysis scripts are available on the OSF (<https://osf.io/hxrmm/>). Confirmatory statistical analysis was pre-registered (<https://osf.io/yc8k2/>) before the experimental work began as outlined in the Registered Report ([@bib8]). Additional exploratory analysis was performed using the excised tumor weights. Data were checked to ensure assumptions of statistical tests were met. A meta-analysis of a common original and replication effect size was performed with a random effects model and the *metafor* package ([@bib16]) (available at: <https://osf.io/jcghv/>). The original study data was extracted *a priori* from the published figures by determining the mean and upper/lower error values for each data point. The extracted data was published in the Registered Report ([@bib8]) and was used in the power calculations to determine the sample size for this study.

Deviations from registered report {#s3-4}
---------------------------------

The source of FBS and DPBS were different than what is listed in the Registered Report, with the used source and catalog number listed above. (note: the original source was not specified). Additional materials and instrumentation not listed in the Registered Report, but needed during experimentation are also listed.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Replication Study: Discovery and Preclinical Validation of Drug Indications using Compendia of Public Gene Expression Data\" for further consideration at *eLife*. Your article has been evaluated by Charles Sawyers as the Senior Editor, a Reviewing Editor, and three reviewers.

There are issues that need to be addressed in a resubmission, as outlined below:

In this manuscript, Kandela and colleagues attempt to replicate prior work by Sirota et al. on the validation of computationally predicted sensitivity to the drug cimetidine in lung but not in renal cancer xenografts. They conclude that the sensitivity to cimetidine of xenografts from A549 lung cancer cells, compared to media control cannot be assessed at a statistically significant level. The authors\' results show a trend of response to cimetidine as the original findings but possibly less potent (less significant).

1\) It is notable that there are variables such as: circadian biological responses to therapy, mouse strain stocks, and the microbiome of recipient mice that may affect the growth of xenografts. As such, it is suggested that the authors provide a discussion that includes variables that were not specifically addressed or could not be easily controlled.

2\) The original study observed a statistically significant reduction in A549 tumor volume while the current study did not, although the direction and magnitude of changes are similar. The number of mice in the study was inferred based on the original study, based on smaller tumor volume measurement errors. The current study conducted pre-planned contrasts on log transformed data within the framework of ANOVA, and the p-values are Bonferroni corrected, while the previous study performed t-tests on un-transformed data without Bonferroni correction. Why is Bonferroni correction used in the new study as opposed to testing directly the single original hypothesis, i.e. that tumor growth of cimetidine treated mice at the highest concentration is reduced compared to PBS/vehicle treatment? We don\'t see the rationale here for introducing a Bonferroni correction. In addition, it is well known that Bonferroni is an ultra-conservative way to account for multiple hypothesis testing. Without Bonferroni correction, the p-value is significant (p = 0.035) despite the larger error size. Please explain and discuss.

3\) Please note that there are more effective models in which the curves can be easily fit by regression analysis (e.g. MANOVA or Regression with RE/AR errors). Such models could be used here. Using the last time point is especially sensitive to measurement errors. It is evident by comparing [Figure 1A](#fig1){ref-type="fig"} to the original plot that the measurement errors incurred by the reproducibility study are substantially larger than those in the original study (Figure 4C). This is a problem also because the same errors were substantially reduced when comparing cimetidine activity to PBS/vehicle in ACHN cells ([Figure 1B](#fig1){ref-type="fig"}). This raises the concern regarding the accuracy of caliper measurements and tumor volume assessment by Kandela et al. Please explain these issues and provide the data plotted as individual xenografts rather than averages in the supplemental data so that readers can examine the extent of mouse to mouse variations.

4\) Please address the following minor issues. There are substantial variability sources in the study that may cause small effect changes. These include:

a\) Drift in the A549 cell line: was this authenticated in the repeated study compared to the original one?

b\) Different compound potency from different stock solutions: were titration curves performed to assess whether the EC50 of the compounds recapitulated those in the original study? This is especially critical since the growth curves at 50mg/kg and 100mg/kg were dramatically different. Thus even a minimal difference in compound potency could induce profound differences in the measurements.

c\) Site of injection: Were the sites identical?
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Author response

*Thank you for submitting your work entitled \"Replication Study: Discovery and Preclinical Validation of Drug Indications using Compendia of Public Gene Expression Data\" for further consideration at eLife. Your article has been evaluated by Charles Sawyers as the Senior Editor, a Reviewing Editor, and three reviewers.*

*There are issues that need to be addressed in a resubmission, as outlined below:*

*In this manuscript, Kandela and colleagues attempt to replicate prior work by Sirota et al. on the validation of computationally predicted sensitivity to the drug cimetidine in lung but not in renal cancer xenografts. They conclude that the sensitivity to cimetidine of xenografts from A549 lung cancer cells, compared to media control cannot be assessed at a statistically significant level. The authors\' results show a trend of response to cimetidine as the original findings but possibly less potent (less significant).*

*1) It is notable that there are variables such as: circadian biological responses to therapy, mouse strain stocks, and the microbiome of recipient mice that may affect the growth of xenografts. As such, it is suggested that the authors provide a discussion that includes variables that were not specifically addressed or could not be easily controlled.*

Thank you for this comment. We agree and have added a paragraph at the end of the Results/Discussion section to comment on this aspect of conducting replications.

*2) The original study observed a statistically significant reduction in A549 tumor volume while the current study did not, although the direction and magnitude of changes are similar. The number of mice in the study was inferred based on the original study, based on smaller tumor volume measurement errors. The current study conducted pre-planned contrasts on log transformed data within the framework of ANOVA, and the p-values are Bonferroni corrected, while the previous study performed t-tests on un-transformed data without Bonferroni correction. Why is Bonferroni correction used in the new study as opposed to testing directly the single original hypothesis, i.e. that tumor growth of cimetidine treated mice at the highest concentration is reduced compared to PBS/vehicle treatment? We don\'t see the rationale here for introducing a Bonferroni correction. In addition, it is well known that Bonferroni is an ultra-conservative way to account for multiple hypothesis testing. Without Bonferroni correction, the p-value is significant (p = 0.035) despite the larger error size. Please explain and discuss.*

We performed Bonferroni correction because of the multiple comparisons (3 in total) that we performed on this experimental design. While this is a more conservative approach to adjust for multiple testing, we accounted for this in our power calculations to ensure the sample size was sufficient. The 2x2 design and the multiple planned contrasts was conducted to test the interaction, which the original study implies when they conclude that a statistically significant difference between vehicle and cimetidine in A549 and no difference between vehicle and cimetidine in ACHN is concordant with their computational prediction. However, the difference between significant and not-significant is not necessarily statistically significant (see: Gelman and Stern, 2006; Nieuwenhuis et al., 2011), which is why the replication study designed and performed the statistical tests this way.

To allow readers to interpret the test results, we report the corrected and uncorrected p values. To further clarify why we performed the ANOVA and multiple comparison corrections we revised the manuscript to explain the analysis and how we accounted for the Bonferroni approach in our sample size calculations.

*3) Please note that there are more effective models in which the curves can be easily fit by regression analysis (e.g. MANOVA or Regression with RE/AR errors). Such models could be used here. Using the last time point is especially sensitive to measurement errors. It is evident by comparing [Figure 1A](#fig1){ref-type="fig"} to the original plot that the measurement errors incurred by the reproducibility study are substantially larger than those in the original study (Figure 4C). This is a problem also because the same errors were substantially reduced when comparing cimetidine activity to PBS/vehicle in ACHN cells ([Figure 1B](#fig1){ref-type="fig"}). This raises the concern regarding the accuracy of caliper measurements and tumor volume assessment by Kandela et al. Please explain these issues and provide the data plotted as individual xenografts rather than averages in the supplemental data so that readers can examine the extent of mouse to mouse variations.*

Thank you for this suggestion. We agree that different models to analyze the data could be used and we encourage others to explore the data this way. This is one of the reasons we are making our raw data available. However, for this specific project we have restricted our analysis to what we specified in the Registered Report and how the sample size was determined. The final caliper measurement was also the approach taken in the original paper. Also, during peer review of the Registered Report we proposed performing an exploratory analysis of all the data, but removed this as suggested by a reviewer since in vivo caliper measurements are noisy, especially with the earlier time-points when the tumors are smaller in size. We have revised the manuscript to communicate how multiple approaches could be taken, but we have limited our analysis to what we proposed.

We have also revised the manuscript to state the error of the measurements between the mice in this replication attempt, which generally had larger relative standard deviations compared to the original study. However, this replication was more consistent among the conditions compared to the original study. (Replication attempt: (A549 -- vehicle treated = 35.6%; A549 -- cimetidine treated = 30.5%; ACHN -- vehicle treated = 32.1%; ACHN -- cimetidine treated = 44.5%). Original study: (A549 -- vehicle treated = 17.0%; A549 -- cimetidine treated = 35.5%; ACHN -- vehicle treated = 10.3%; ACHN -- cimetidine treated = 12%)). Additionally, we have included a supplement figure for [Figure 1](#fig1){ref-type="fig"}, ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), which plots the data for each individual animal rather than the averages.

*4) Please address the following minor issues. There are substantial variability sources in the study that may cause small effect changes. These include:*

*a) Drift in the A549 cell line: was this authenticated in the repeated study compared to the original one?*

We confirmed the A549 and ACHN cells were correct by STR profile and free of mycoplasma and rodent pathogens. However, we do not know the profile of the original cell lines as these were not shared, nor was the source of the cell lines identified in the original study. We have included this aspect as a feature that might be critical, but unidentified at the end of the Results/Discussion section.

*b) Different compound potency from different stock solutions: were titration curves performed to assess whether the EC50 of the compounds recapitulated those in the original study? This is especially critical since the growth curves at 50mg/kg and 100mg/kg were dramatically different. Thus even a minimal difference in compound potency could induce profound differences in the measurements.*

We did not perform titration curves in this replication. We agree that slight differences in compound potency can affect the outcome of the experiment. We have included this aspect as a feature that might be critical, but not controlled for at the end of the Results/Discussion section.

*c) Site of injection: Were the sites identical?*

The injection site in the original paper was reported as occurring in the upper flank of the animals and intraperitoneally. This was the same for the replication attempt.
